Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis
Ilse Daehn, … , Borje Haraldsson, Erwin P. Bottinger
Ilse Daehn, … , Borje Haraldsson, Erwin P. Bottinger
Published March 3, 2014
Citation Information: J Clin Invest. 2014;124(4):1608-1621. https://doi.org/10.1172/JCI71195.
View: Text | PDF
Research Article Nephrology

Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis

  • Text
  • PDF
Abstract

Focal segmental glomerular sclerosis (FSGS) is a primary kidney disease that is commonly associated with proteinuria and progressive loss of glomerular function, leading to development of chronic kidney disease (CKD). FSGS is characterized by podocyte injury and depletion and collapse of glomerular capillary segments. Progression of FSGS is associated with TGF-β activation in podocytes; however, it is not clear how TGF-β signaling promotes disease. Here, we determined that podocyte-specific activation of TGF-β signaling in transgenic mice and BALB/c mice with Adriamycin-induced glomerulosclerosis is associated with endothelin-1 (EDN1) release by podocytes, which mediates mitochondrial oxidative stress and dysfunction in adjacent endothelial cells via paracrine EDN1 receptor type A (EDNRA) activation. Endothelial dysfunction promoted podocyte apoptosis, and inhibition of EDNRA or scavenging of mitochondrial-targeted ROS prevented podocyte loss, albuminuria, glomerulosclerosis, and renal failure. We confirmed reciprocal crosstalk between podocytes and endothelial cells in a coculture system. Biopsies from patients with FSGS exhibited increased mitochondrial DNA damage, consistent with EDNRA-mediated glomerular endothelial mitochondrial oxidative stress. Our studies indicate that segmental glomerulosclerosis develops as a result of podocyte-endothelial crosstalk mediated by EDN1/EDNRA-dependent mitochondrial dysfunction and suggest that targeting the reciprocal interaction between podocytes and endothelia may provide opportunities for therapeutic intervention in FSGS.

Authors

Ilse Daehn, Gabriella Casalena, Taoran Zhang, Shaolin Shi, Franz Fenninger, Nicholas Barasch, Liping Yu, Vivette D’Agati, Detlef Schlondorff, Wilhelm Kriz, Borje Haraldsson, Erwin P. Bottinger

×

Figure 1

Activation of podocyte-specific TGFβR1 induces podocytopathy with progressive glomerular disease and renal failure.

Options: View larger image (or click on image) Download as PowerPoint
Activation of podocyte-specific TGFβR1 induces podocytopathy with progre...
Representative glomerular triple-immunofluorescence staining in PodTgfbr1 mice on (A) regular chow and (B) after 2 days of Dox chow, showing SMAD2/3 and DAPI and SMAD2/3 and WT1 localization. Arrows depict nuclear WT1 and DAPI in podocytes in A and colocalization with SMAD2/3 in B. Arrowheads denote cytoplasmic SMAD2/3 staining. (C) Superresolution image of SMAD2/3 (red) specifically localized to WT1- (green) and DAPI-positive (blue) cells. (D) ACR in PodTgfbr1 mice treated with Dox (days 0–14; n = 6 mice per group) and serum creatinine in Dox-treated PodTgfbr1 mice (n = 5 mice per group; mean ± SEM). (E–H) Histopathology stain (PAS) of PodTgfbr1 mice: (E) control mice without Dox, (F) day 4 of Dox, (G) day 14 of Dox, and (H) day 14 of Dox. (I) Podocyte number (gray bars) and podocyte apoptosis (black line) of Dox-treated PodTgfbr1 mice (mean ± SD; >50 glomerular profiles per mouse; >5 mice per time point). (J) Ultrastructural analysis by electron microscopy of day 4 Dox PodTgfbr1 mice. Glomerular area with mesangial expansion and endothelial cells (E) that protrude (arrows) and shed material (asterisks) into capillary lumens. Podocytes show normal foot process pattern (arrowheads). MC, mesangial cell. (K) Electron microscopy images of day 7 Dox PodTgfbr1 mice. Glomerular area with similar mesangial and endothelial changes. Podocytes show extensive foot process effacement (arrowheads). Scale bar: 50 μm (A, B, and E–H); 5 μm (J and K). Original magnification, ×63 (A, B, and E–G); ×100 (C); ×20 (H). *P < 0.05, **P < 0.01, ***P < 0.001 versus controls.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts